National Institutes of Health Grants

National Institutes of Health · Amount varies

This NIH/NIMH R34 grant supports pilot research to adapt, optimize, and test behavioral interventions for sleep problems in adolescents and young adults with or at risk for a mental health disorder, and a clinical trial is required. It is a research grant for universities, research institutions, and similar eligible organizations. Foreign (non-U.S.) organizations and foreign components are not eligible. No specific award amounts are listed, and eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.

National Institutes of Health · Up to $1.3M

This NIH U01 grant establishes the GREGoRi Data Coordination and Outreach Center, which coordinates the rare disease research program and makes its protocols, data, tools, and resources available to the broader community; clinical trials are not allowed. It is a research grant for universities, research institutions, and similar eligible organizations. Foreign organizations and foreign components are not eligible to apply. The award maximum is about $1.25 million. Eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.

National Institutes of Health · Up to $2.3M

This NIH U01 grant establishes the GREGoRi Technology Integration Center to set standards and best practices for applying new molecular methods in rare disease diagnosis, including building a benchmarking dataset; clinical trials are optional. It is a research grant for universities, research institutions, and similar eligible organizations. Foreign organizations and foreign components are not eligible to apply. The award maximum is about $2.25 million. Eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.

National Institutes of Health · Amount varies

This NIH X01 opportunity provides access to biospecimens (urine, plasma, serum, genomic DNA) and related data from the Population Assessment of Tobacco and Health (PATH) Study rather than direct research funding. It is aimed at investigators at universities, research institutions, and similar eligible organizations, including various minority-serving institutions and tribal entities. Foreign (non-U.S.) organizations and foreign components are not eligible. No award amounts are listed; this is a resource-access mechanism for researchers, not a general grant for nonprofits, businesses, or individuals.

National Institutes of Health · $3–$500K

This NIH U01 grant funds development and testing of highly innovative experimental or computational approaches for rare disease diagnosis, with clinical trials optional. It is a research grant for universities, research institutions, and similar eligible organizations, and foreign organizations and foreign components are eligible. The award maximum is about $500,000 (the listed minimum appears to be a data artifact). Eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.

National Institutes of Health · Amount varies

This NIH R61 grant supports exploratory clinical trials in arthritis, musculoskeletal, and skin diseases, and a clinical trial is required. It is a research grant for universities, research institutions, and similar eligible organizations, including various minority-serving institutions and tribal entities. Foreign (non-U.S.) organizations are not eligible to apply, though defined foreign components are allowed. No specific award amounts are listed, and eligibility is oriented toward research institutions rather than nonprofits, small businesses, or individuals broadly.

National Institutes of Health · Amount varies

This NIH R01 grant funds clinical observational studies in musculoskeletal, rheumatic, and skin diseases. It is a research grant for universities, research institutions, and similar eligible organizations, including various minority-serving institutions and tribal entities. Foreign (non-U.S.) organizations are not eligible to apply, though defined foreign components are allowed; clinical trials are not permitted under this opportunity. No specific award amounts are listed, and eligibility is oriented toward research institutions rather than nonprofits, small businesses, or individuals broadly.

National Institutes of Health · Amount varies

This NIH R01 grant supports development of novel theory and methods to understand how genetic and non-genetic factors shape complex human traits, using interdisciplinary modeling and large-scale datasets. It is a research grant aimed primarily at universities, research institutions, and similar eligible organizations, including various minority-serving institutions, tribal entities, and foreign organizations. No award amounts are specified. Clinical trials are not allowed under this opportunity, and the eligibility list is research-institution oriented rather than open to nonprofits, small businesses, or individuals broadly.

National Institutes of Health · Up to $350K

This NIH/NCI R01 grant funds secondary analysis and integration of existing datasets to study cancer risk and related outcomes such as survival and treatment response. It is a research grant for universities, research institutions, and similar eligible organizations, including various minority-serving institutions, tribal entities, and foreign organizations. The award maximum is about $350,000. Eligibility is oriented toward research institutions rather than nonprofits, small businesses, or individuals broadly, and applicants typically need access to relevant existing data.

National Institutes of Health · Up to $150K

This NIH/NCI R61 grant funds early-stage, proof-of-concept development of innovative technologies for molecular or cellular characterization of cancer and biospecimen handling; clinical trials are not allowed. It is a research grant for universities, research institutions, and similar eligible organizations, and foreign organizations and foreign components are eligible. The award maximum is about $150,000. Eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.

National Institutes of Health · Amount varies

This NIH U01 grant funds research using expanded-access data for investigational drugs to help intermediate-size populations of ALS patients who are not eligible for ongoing clinical trials; a clinical trial is required. Eligibility is narrow: applicants must be clinical trial sites participating in a phase 2/3 or phase 3 trial sponsored by a small business that is the FDA-designated sponsor of the relevant drug. Foreign organizations and foreign components are not eligible. No award amounts are listed. This is a highly specialized opportunity tied to an existing small-business-sponsored ALS drug trial, not a general grant.

National Institutes of Health · Up to $300K

This NIH/NCI R33 grant funds advanced development and technical validation of emerging technologies for molecular or cellular characterization of cancer and biospecimen handling, where feasibility has been shown but further validation is needed; clinical trials are not allowed. It is a research grant for universities, research institutions, and similar eligible organizations, and foreign organizations and foreign components are eligible. The award maximum is about $300,000. Eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.

National Institutes of Health · Up to $1.1M

NIH (NCCIH) R33 funding for early-phase clinical trials of natural products (botanicals, dietary supplements, probiotics) to confirm target engagement and inform whether further clinical research is warranted. Intended for research institutions; foreign organizations are not eligible. The listed maximum is about $1,050,000. It will not support efficacy or effectiveness trials and requires strong preliminary data, making it narrow research-only funding.

National Institutes of Health · Up to $750K

NIH (NIDA) K12 institutional career-development funding to support mentored research training for clinician-scientists in substance use and substance use disorder research. Intended for institutions that will run a scholar training program; foreign organizations are not eligible and foreign components are not allowed. The listed maximum is about $750,000. This is an institutional training award, not a grant for individuals or general nonprofits.

National Institutes of Health · Amount varies

NIH (NCCIH) R01 funding for mid-phase clinical trials of natural products such as botanicals, dietary supplements, and probiotics that already have strong preliminary data. Intended for research institutions able to conduct hypothesis-driven, milestone-based clinical trials; foreign organizations are not eligible. No dollar amount is stated. It will not support efficacy/effectiveness trials or cancer-treatment trials, and requires substantial prior preliminary data, so it is narrow in scope.

National Institutes of Health · Up to $350K

NIH (NCCIH) phased R61/R33 funding for early-phase clinical trials of natural products (botanicals, probiotics, marketed dietary supplements) with a strong scientific rationale. Suited to research institutions running milestone-driven pharmacokinetic and target-engagement studies; foreign organizations are not eligible. The listed maximum is about $350,000. It is narrow research-only work requiring strong preliminary justification, not a fit for individuals or general nonprofits.

National Institutes of Health · Up to $50K

This NIH grant (up to $50,000) funds small research projects studying the ethical, legal, and social implications (ELSI) of human genetics and genomics, including single-investigator studies, preliminary data collection, and secondary data analysis. It's aimed at eligible U.S. and territorial research institutions. The deadline is November 16, 2026.

National Institutes of Health · Amount varies

This NIH R01 funds investigator-initiated, fully remote clinical trials testing complementary and integrative health interventions (with no in-person contact and possible mHealth tools) in NCCIH's priority research areas. Applicants must justify the remote approach and provide feasibility and safety preliminary data. It's aimed at eligible U.S. research institutions, and the deadline is November 17, 2026.

National Institutes of Health · Amount varies

NIH (NIAAA) phased R61/R33 funding for research on preventing prenatal alcohol exposure and developing interventions for fetal alcohol spectrum disorders. Intended for research institutions and investigators, including minority-serving and tribal colleges; advancement to the R33 phase depends on meeting milestones. No award amount is stated. This is institution-based research funding with priority for clinical-trial applications, not suited to individuals or general nonprofits.

National Institutes of Health · Up to $200K

NIH (NCI) R21 funding for secondary analysis and integration of existing datasets to study cancer risk and related outcomes; clinical trials are not allowed under this notice. Intended for research institutions and investigators, including minority-serving and tribal colleges. The listed maximum is about $200,000. This is institution-based research funding using existing data, not suited to individuals or general nonprofits.